share_log
Breakings ·  Dec 10 21:05
Imunon Announces Continued Strong Improvement in Overall Survival Data From Randomized Phase 2 Ovation 2 Study of Imnn-001
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment